Influx Healthtech

Influx Healthtech Limited - IPO

SME

Influx Healthtech IPO Details

Open Date
18 Jun 2025
Close Date
20 Jun 2025
Listing Date
25 Jun 2025
Issue Price
₹91 - ₹96
Face Value
₹10 per share
Lot Size
1200
GMP
₹37 (38.5%)
Issue Type
IPO
Listing On
NSE
Type
Book Built Issue
Share holding pre issue
18150000
Share holding post issue
23150400
Total Issue Size
61,00,800 shares (aggregating up to ₹58.57 Cr)
Fresh Issue
50,00,400 shares (aggregating up to ₹48.00 Cr)
Offer for Sale
11,00,400 shares (aggregating up to ₹10.56 Cr)

Influx Healthtech IPO Dates

  • 18 Jun 2025
    Opening dateOPD
  • 20 Jun 2025
    Closing dateCOD
  • 23 Jun 2025
    Basis of AllotmentBOA
  • 24 Jun 2025
    Initiation of RefundsIOR
  • 24 Jun 2025
    Credit of SharesCOS
  • 25 Jun 2025
    Listing dateLID

Influx Healthtech IPO Lot Size

ApplicationLotsSharesAmount
Retain Minimum11200₹115,200
Retain Maximum11200₹115,200
HNI Minimum22400₹230,400

Influx Healthtech IPO Reservation

Promoter Holding

Pre Issue:99.85%
Post Issue:73.53%
Promoter Names:
Mr. Munir Abdul Ganee Chandniwala, Mrs. Shirin Munir Ahmed Chandniwala, Mr. Abdul Ganee Abdul Rasul Chandniwala

Influx Healthtech IPO Valuations

ROE:36.98%
ROCE:49.17%
DEBT/EQUITY:0.01
RONW:36.98%
PAT MARGIN:12.75
PRICE TO BOOK VALUE:7.62
EPS Pre IPO:7.36
EPS Post IPO:5.77
P/E Pre IPO:13.04
P/E Post IPO:16.63

Influx Healthtech Limited Financial Information

Period Ended31 Mar 202531 Mar 202431 Mar 2023
Assets70.3041.1028.30
Revenue104.99100.1076.07
Profit After Tax13.3711.227.20
Net Worth36.1522.8711.65
Reserves and Surplus18.0022.8511.63
Total Borrowing0.220.320.80
Amount in ₹ Crore

About Influx Healthtech IPO

Incorporated in September 2020, Influx Healthtech Limited is a healthcare-focused company specialising in contract manufacturing. The company is a reliable CDMO, providing specialized services to clients in multiple industries.

The company has three manufacturing facilities in Thane, Maharashtra, each covering an area of 9,676 square feet, 13,000 square feet, and 14,000 square feet, respectively.

Product Portfolio:

  • Tablets, Capsules, and Powders
  • Liquid Orals and Softgels
  • Lozenges, Jellies, and Gummies
  • Oral Dispersible Films (ODFs)
  • Effervescent Tablets and Liquid-Fill Capsules
  • Candies and Gym/Sports Supplements
  • Skin Care and Body Care Products
  • Hair Care and Beard Care Solutions
  • Face Masks and Soaps.
  • Ayurvedic / Herbal formulations
  • Veterinary Feed Supplements
  • Homecare solutions

The Company aids Nutraceutical and Cosmetic firms with product development and manufacturing. It offers end-to-end services, including development, production, and regulatory support, enabling clients to focus on formulation and commercialization.

As of June 11, 2025, the company has 163 permanent employees on a payroll basis.

Strength Of Influx Healthtech IPO

1. Diverse client base with longstanding CDMO relationships.

2. Well versed and equipped advanced manufacturing facilities with global accreditations.

3. Large and rapidly growing R&D capabilities across our product portfolio.

4. Experienced Promoter and management team with strong industry expertise and successful track record.

5. Robust Quality Assurance & Control practices.

6. Proven Track record of growth and profitability.

Risk Of Influx Healthtech IPO

1. The Company is reliant on the demand from the nutraceutical industry for a significant portion of its revenue. Any downturn in the nutraceutical industry or an inability to increase or effectively manage its sales could have an adverse impact on the Company's business and results of operations.

2. Its existing manufacturing facility are concentrated in a single region i.e., Palghar, Thane, Maharashtra and the inability to operate and grow its business in this particular region may have an adverse effect on its business, financial condition, results of operations, cash flows and future business prospects.

3. The Company is dependent on few numbers of customers for sales. Loss of any of this large customer may affect its revenues and profitability.

4. The company has historically derived, and may continue to derive, a signification of its supply from top 10 Suppliers. Also, the Company has not entered into long-term agreements with these suppliers. In the event the company is unable to procure adequate amounts of raw materials, at competitive prices its business, results of operations and financial condition may be adversely affected.

5. Too much Geographical concentration of its Business on specific location can impact the company Business.

6. Its reliance on certain industries for a significant portion of its sales could have an adverse effect on its business.

7. The company has not taken any steps to order the machinery/equipment required for the proposed expansion. In the event of any delay in placing the orders, or in the event the vendors are not able to provide the equipment / machineries in a timely manner, or at all, the same may result in time and cost over-runs.

8. Its business activities are exposed to fluctuations in the prices of raw materials.

9. Its may face several risks associated with the construction of the building of the Proposed Expansion, which could hamper its growth, prospects, cash flows and business and financial condition.

10. Its Registered Office, Factory Units and Godown is located on premises which are not owned by it and has been obtained on license basis from the promoters of the company. Disruption of its rights as licensee/ lessee or termination of the agreements with its licensors/ lessors (promoters) may adversely impact its operations and, consequently, its business, financial condition and results of operations.

Objectives Influx Healthtech IPO

1. Funding capital expenditure requirements for setting up of manufacturing facility for Nutraceutical Division

2. Funding capital expenditure requirements for setting up of manufacturing facility for Veterinary Food Division

3. Purchase of Machineries for Homecare and Cosmetic Division

4. General corporate purposes

Company Contact Details

Influx Healthtech Limited
109, Ghanshyam Enclave Premises Co-op
Soc Plot No. 856, Laljipada
Kandivali West,
Mumbai, Maharashtra
Phone: +91 7045997809
Email: cs@influxhealthtech.com
Website: https://influxhealthtech.com/

Registrar Contact Details

Name: Maashitla Securities Private Limited
Phone: +91-11-45121795, +91-11-45121796

Lead Mangers

  1. Rarever Financial Advisors Pvt. Ltd. Pvt. Ltd.

Market Maker

  1. R.K.Stock Holding

Comments